Switching from Rexulti to Seroquel: Tapering Requirements
You do not need to taper off Rexulti (brexpiprazole) before starting Seroquel (quetiapine), but a gradual cross-titration is the preferred approach to minimize risk of psychotic relapse or withdrawal symptoms. 1
Recommended Switching Strategy
The optimal method is gradual cross-titration, where you slowly decrease Rexulti while simultaneously increasing Seroquel, informed by the half-life and receptor profiles of each medication. 1
Key Pharmacological Considerations
- Rexulti (brexpiprazole) is a D2 partial agonist with a long half-life (approximately 91 hours), meaning it takes considerable time to clear from your system 2
- Seroquel (quetiapine) is a D2 antagonist with a much shorter half-life, requiring different dosing considerations 3
- The pharmacodynamic difference between these agents (partial agonist vs. antagonist) makes gradual cross-titration particularly important to avoid receptor-related complications 1
Practical Switching Approach
For Seroquel initiation during cross-titration: 3
- Day 1: 50 mg
- Day 2: 100 mg
- Day 3: 200 mg
- Day 4: 300 mg
- Day 5: 400 mg (target therapeutic dose)
- Administer twice daily in divided doses
Simultaneously taper Rexulti gradually over this same period, though the specific taper schedule should account for its long half-life. 1
Important Caveats
- Abrupt discontinuation studies: While research shows that abrupt switches to or from quetiapine don't produce significant clinical consequences in controlled settings, real-world practice demands individualized caution to minimize psychotic relapse risk 3
- Monitor closely for 4+ weeks: Given that therapeutic response assessment requires at least 4 weeks at therapeutic doses, close monitoring during and after the switch is essential 1
- Drug interactions are minimal: No significant pharmacokinetic interactions exist between these medications that would complicate switching 2
Clinical Monitoring During Switch
Watch for:
- Extrapyramidal symptoms as you transition from partial agonist to antagonist activity 2
- Metabolic changes, as both medications carry metabolic risks but with different profiles 2
- Sedation, particularly as quetiapine has more prominent sedating effects than brexpiprazole 3
- Emergence or worsening of psychotic symptoms during the transition period 1